You are here

Incyte

Incyte’s good week continues with an encouraging update on IDO1 star epacadostat

Incyte’s good week continues with an encouraging update on IDO1 star epacadostat

Endpoints

Flag link:

Incyte, Merck build case for skin cancer combo

Incyte, Merck build case for skin cancer combo

BioPharma Dive

advanced melanoma

Flag link:

3 Most Promising Cancer Drugs in Late-Stage Development

3 Most Promising Cancer Drugs in Late-Stage Development

Motley Fool

advanced breast cancer

prostate cancer

Flag link:

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

EP Vantage

Portola Pharmaceuticals

DBV Technologies

Flag link:

Tesaro's rumored buyers aren't biting. Should Gilead go for Incyte instead?

Tesaro's rumored buyers aren't biting. Should Gilead go for Incyte instead?

Fierce Pharma

Gilead Sciences

Flag link:

Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive

Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive

Endpoints

Gilead Sciences

Vertex Pharmaceuticals

Flag link:

3 Biotech Stocks That Could Become M&A Targets

3 Biotech Stocks That Could Become M&A Targets

Motley Fool

Flag link:

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Endpoints

non-small cell lung cancer

Flag link:

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

Endpoints

PDL-1 inhibitors

NewLink Genetics

Juno Therapeutics

Bristol-Myers Squibb

Flag link:

7 Areas to watch from the ASCO abstracts

7 Areas to watch from the ASCO abstracts

BioPharma Dive

NewLink Genetics

Juno Therapeutics

Flag link:

Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo

Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo

Endpoints

non-small cell lung cancer

Flag link:

Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid

Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid

Endpoints

Hervé Hoppenot

Flag link:

The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling

The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling

Yahoo/Business Insider

rheumatoid arthritis

Flag link:

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

TheStreet.com

small cell lung cancer

Flag link:

Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug

Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug

Marketwatch

rheumatoid arthritis

Flag link:

Traders say mergers and acquisitions could bring boost to biotech stocks

Traders say mergers and acquisitions could bring boost to biotech stocks

CNBC

Flag link:

We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble

We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble

Endpoints

Flag link:

3 Big Drugmakers Most Likely to Buy Incyte

3 Big Drugmakers Most Likely to Buy Incyte

Motley Fool

Gilead Sciences

Bristol-Myers Squibb

Flag link:

Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?

Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?

Barron's

immuno-oncology

Flag link:

Would Gilead Sciences Make This Staggeringly Audacious Move?

Would Gilead Sciences Make This Staggeringly Audacious Move?

Motley Fool

Gilead Sciences

Flag link: